The largest drug companies are far more interested in enriching themselves and investors than in developing new drugs, according to a House committee report released Thursday that argues the industry can afford to charge Medicare less for prescriptions. The report by the House Oversight and Reform Committee says that contrary to pharmaceutical industry arguments that